Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Oncolys’ Telomelysin Wins Backing from Japan Panel
A Japanese health ministry panel on May 21 recommended approval for Oncolys BioPharma’s oncolytic virus therapy Telomelysin (suratadenoturev) for esophageal cancer. The Pharmaceutical Affairs Council’s Committee on Regenerative Medicine Products, Biological Products and Biotechnologies endorsed the product for standard approval,…
To read the full story
Related Article
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- ONODERA GT’s Parkinson’s Gene Therapy Gets Sakigake Tag
June 10, 2026
- Oncolys Targets 300 Hospitals for Telomelysin Rollout
June 9, 2026
- Japan Approves Oncolys’ Telomelysin for Esophageal Cancer
June 8, 2026
- Oncolys’ Telomelysin Up for Japan Panel Review on May 21
May 15, 2026
- ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
REGULATORY
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
- Japan Moves to Add Ceftriaxone to Economic Security List
July 1, 2026
- LDP Group Submits Honebuto Proposal, Urges Pediatric Cancer Platform
July 1, 2026
- Lower House Clears Immunization Act Revision
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…